Actavis PLC (ACT): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Actavis ( ACT) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.1%. By the end of trading, Actavis rose $6.52 (3.3%) to $204.33 on average volume. Throughout the day, 3,800,359 shares of Actavis exchanged hands as compared to its average daily volume of 2,973,900 shares. The stock ranged in a price between $200.12-$205.44 after having opened the day at $203.50 as compared to the previous trading day's close of $197.81. Other companies within the Health Care sector that increased today were: AVANIR Pharmaceuticals ( AVNR), up 45.6%, IsoRay ( ISR), up 29.6%, Adamas Pharmaceuticals ( ADMS), up 15.3% and 22nd Century Group ( XXII), up 14.0%.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $34.4 billion and is part of the drugs industry. Shares are up 17.7% year to date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Actavis a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk.

On the negative front, Synthetic Biologics ( SYN), down 30.9%, Auxilium Pharmaceuticals ( AUXL), down 17.7%, Prothena ( PRTA), down 15.8% and Usana Health ( USNA), down 15.7% , were all laggards within the health care sector with GlaxoSmithKline ( GSK) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers